The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group.
P. Harter
Honoraria - Essex Pharma
Research Funding - Essex Pharma
U. Canzler
No relevant relationships to disclose
H. Lueck
No relevant relationships to disclose
A. Reuss
No relevant relationships to disclose
W. Meier
No relevant relationships to disclose
T. N. Fehm
No relevant relationships to disclose
A. Staehle
No relevant relationships to disclose
A. Burges
No relevant relationships to disclose
C. Kurzeder
No relevant relationships to disclose
J. Sehouli
No relevant relationships to disclose
K. H. Baumann
No relevant relationships to disclose
L. C. Hanker
No relevant relationships to disclose
P. Wimberger
No relevant relationships to disclose
W. Schroeder
No relevant relationships to disclose
M. Gropp
No relevant relationships to disclose
S. Mahner
Consultant or Advisory Role - Essex Pharma
Honoraria - Essex Pharma; Merck Sharp & Dohme; PharmaMar
A. Du Bois
Honoraria - Schering-Plough
Research Funding - Schering-Plough